Deloitte.





Deloitte Corporate Finance's Life Sciences & Health Care Practice

Deloitte Corporate Finance LLC (DCF) is a leading, global middle-market M&A adviser. Our professionals have extensive knowledge in the life sciences and health care spaces and use their experience to help clients enhance value.



Life Sciences & Health Care Leadership





Firm Overview

Sector Focus



Simon Gisby New York, NY







Newman Delany Tampa, FL ndelany@deloitte.com



Eric Steinberg Charlotte, NC esteinberg@deloitte.com



Daniel Levy Charlotte. NC daniellevy@deloitte.com



AJ Silverman Charlotte. NC ajsilverman@deloitte.com


2022 Global M&A Advisor by deals completed.(1)

Completed deals in 2022.

- Deep relationships in place to gain critical strategic intelligence and effectively market businesses.
- Worldwide, DCF has 2,400 Corporate Finance professionals throughout the Deloitte Touche Tohmatsu Limited network of member firms in 60 countries that complement the North American team.
- Top global middle-market financial advisor in 2022 according to Mergermarket.(1)

- Health care services
- Health care technology
- Life sciences & pharma services
- Medical devices & supplies
- Payors & payor services

Table of contents





Rural Health Alliance



Client Overview

 Rural Health Alliance, LLC is an operator of 15 rural walk-in clinics providing primary care and integrated ancillary services, such as behavioral health and pediatric care, in Western and Middle Tennessee.

"Deloitte Corporate Finance delivered high touch advisory services at every stage of the sale process. Their experience working with health care services businesses, particularly in the primary care space; deep private equity relationships; and premier execution capabilities enabled Rural Health Alliance to secure a fantastic valuation and overcome the unique challenges presented during the global COVID-19 pandemic."

- Ruste Via, President and CEO

Workplace Options



Client Overview

Workplace Options, LLC is a corporate wellness solutions and supplemental health benefits provider offering behavioral health, as well as practical and physical wellbeing support, to employees and their families across the globe.

"Deloitte Corporate Finance's guidance and industry experience allowed Workplace Options to accomplish its financial and operational objectives. The detailed process included in-depth due diligence and extensive pre-market analysis on several strategic alternatives. These options were presented with great clarity by the Deloitte team. Additionally, by running a highly disciplined and structured marketing process, DCF effectively maintained stiff competition, which enabled us to negotiate transaction terms that exceeded our expectations."

NetCE



Client Overview

 CE Resource, Inc. is one of the leading providers of continuing education to health care practitioners in the United States.

"Deloitte Corporate Finance's knowledge of the education and training space was evident from day one. Their team drove an efficient and competitive process offering invaluable strategic guidance every step of the way, ultimately providing our team with numerous actionable offers at attractive valuations."

- Lisa Patterson, CEO

Prior engagement performance is no guarantee of future performance and may not be representative of the experience of other clients. This communication is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security.

- Alan King, President and CEO

Deloitte thought leadership

- Deloitte stays abreast of industry trends and makes significant investments in producing cutting-edge thought leadership.
- Deloitte is deeply committed to providing insights that help keep clients on the forefront of critical trends.
- Focused research on industry drivers and trends helps enables Deloitte to demonstrate eminence in the life sciences and health care market by redefining the lens through which industry leaders operate.

Extensive knowledge network

DCF leverages its
 expansive, cross-business
 knowledge network,
 extensive consulting
 reports, and in-depth
 industry research to drive
 results and provide
 differentiated insights
 for our clients.



Build Knowledge

Recent insights









Health care services

Sector Trends (1)


Health care service providers continue to experience margin contraction due to inflationary pressures, staffing shortages, and supply chain disruptions. This is driving hospital systems to diversify service offerings by acquiring ambulatory sites, digital health platforms, primary care clinics, and post-acute care clinics. Many service providers are also pursuing strategic partnerships with innovators in the space to enter new geographic regions and expand the providers' patient base.


Select Recent M&A Activity⁽²⁾

| Close Date | Target | Acquiror | Implied EV (\$M) |
|------------|-------------------------------------|-----------------------------------|------------------|
| Feb 2023 | LHC Group | Optum | \$6,153.6 |
| Feb 2023 | One Medical | Amazon | \$4,008.1 |
| Feb 2023 | Springstone | LifePoint Health | \$250.0 |
| Jan 2023 | Summit Medical Group | VillageMD | \$8,900.0 |
| Jan 2023 | Greenbrier Valley Medical Center | Charleston Area Medical Center | \$85.1 |



| Company Name | Enterprise Value (\$M) |
|--------------------------|------------------------|
| DaVita Inc. | \$20,604.1 |
| Quest Diagnostics Inc. | \$20,437.7 |
| Oak Street Health, Inc. | \$10,417.6 |
| Option Care Health, Inc. | \$6,557.3 |
| Amedisys, Inc. | \$3,191.0 |
| Cano Health. | \$1,762.7 |






Health care technology

Sector Trends (1)

Data and advanced analytics continue to drive innovation in population health management, revenue cycle management, and patient engagement. Many providers also continue to invest in operational capabilities and technology infrastructure to position their organizations for a shift toward value-based care. These trends are driven by patients who are playing a more active role in managing their health through new digital tools including wellness apps, fitness trackers, other wearables, and remote monitoring devices.


Select Recent M&A Activity⁽²⁾


| Close Date | Target | Acquiror | Implied EV (\$M) |
|------------|----------------|---------------------|------------------|
| Mar 2023 | GiftHealth. | Eir Partners | \$40.0 |
| Mar 2023 | Signify Health | CVS Health | \$8,000.0 |
| Mar 2023 | DoseMe | Fairlong Capital | N/A |
| Feb 2023 | MphRx | Agilon Health | \$45.0 |
| Jan 2023 | BurnAlong | Stone Point Capital | N/A |



Select Public Comparables⁽³⁾

| Company Name | Enterprise Value (\$M) |
|---------------------------|------------------------|
| Veeva Systems, Inc. | \$25,554.1 |
| MultiPlan Corporation | \$5,151.4 |
| Teladoc Health, Inc. | \$4,874.8 |
| Omnicell, Inc. | \$2,977.0 |
| Health Catalyst, Inc. | \$603.8 |
| American Well Corporation | \$70.9 |
| | |






Life sciences and pharma services

Sector Trends (1)


Macroeconomic headwinds and shorter patent timeframes are placing greater pressure on pharmaceutical companies to innovate and remain competitive. These challenges are exacerbated by the Inflation Reduction Act, which continues to lower drug prices and profit margins. In response, pharmaceutical companies are focused on improving operational efficiencies, diversifying products and revenue streams, and increasing strategic acquisitions to gain scale.


Select Recent M&A Activity⁽²⁾

| Target | Acquiror | Implied EV (\$M) |
|-------------------------------|---|---|
| Myovant Sciences Ltd. | Sumitovant Biopharma Ltd. | \$1,347.7 |
| Concert Pharmaceuticals, Inc. | Sun Pharmaceutical Industries Limited | \$842.7 |
| CinCor Pharma, Inc. | AstraZeneca, PLC | \$1,657.4 |
| The Binding Site Group, Ltd. | Thermo Fisher Scientific Inc. | \$2,586.5 |
| PharmaLex Holding GmbH | AmerisourceBergen Corporation | \$1,296.7 |
| | Myovant Sciences Ltd. Concert Pharmaceuticals, Inc. CinCor Pharma, Inc. The Binding Site Group, Ltd. | Myovant Sciences Ltd. Concert Pharmaceuticals, Inc. Sun Pharmaceutical Industries Limited CinCor Pharma, Inc. AstraZeneca, PLC The Binding Site Group, Ltd. Thermo Fisher Scientific Inc. Pharmal ex Holding GmbH AmerisourceBergen |



| Company Name | Enterprise Value (\$M) |
|-------------------------------|------------------------|
| AbbVie Inc. | \$341.8 |
| Merck & Co., Inc. | \$307.5 |
| Thermo Fisher Scientific Inc. | \$251.3 |
| Pfizer Inc. | \$250.4 |
| Amgen Inc. | \$163.6 |
| IQVIA Holdings Inc. | \$48.8 |
| | |





Medical devices and supplies

Sector Trends (1)

After the rise in virtual health utilization during the pandemic, patients are now accustomed to telehealth services that increase convenience. The growth in digital health wearables and remote monitoring devices has enabled patients and providers to track health metrics and improve outcomes. Patients are now in greater control of managing their health through a rise in personalized medicine and technological innovation. The market for implantable and prosthetic devices continues to expand, leading to increased competition. Companies have diversified marketing strategies to target both patients and providers to maximize market share.


Select Recent M&A Activity⁽²⁾


| Close Date | Target | Acquiror | Implied EV (\$M) |
|------------|-------------------------------|------------------------------|------------------|
| Mar 2023 | Immucor, Inc. | Werfen, S.A. | \$2,000.0 |
| Feb 2023 | Embody, Inc. | Zimmer Biomet Hodlings, Inc. | \$280.9 |
| Jan 2023 | AcuFocus, Inc. | Bausch + Lomb Corporation | \$35.0 |
| Jan 2023 | SeaSpine Holdings Corporation | Orthofix Medical Inc. | \$328.3 |
| Jan 2023 | MGC Diagnositcs Corporation | CAIRE, Inc. | \$170.2 |



| Company Name | Enterprise Value (\$M) |
|---------------------|------------------------|
| Johnson & Johnson | \$445.9 |
| Abbott Laboratoires | \$186.2 |

| Medtronic plc | \$124.6 |
|-------------------------------|---------|
| Stryker Corporation | \$121.5 |
| Becton, Dickinson and Company | \$87.9 |
| Baxter International Inc. | \$37.1 |





Payors and payor services

Sector Trends (1)


Inflationary concerns are pushing payors to invest in innovative cost-containment solutions that leverage machine learning and artificial intelligence to analyze data and improve operational efficiencies. Employers continue to pursue ways to contain employee healthcare benefit costs while improving health outcomes, leading to the adoption of value-based care plans.


Select Recent M&A Activity⁽²⁾

| Close Date | Target | Acquiror | Implied EV (\$M) |
|------------|----------------------------|----------------------|------------------|
| Mar 2023 | Signify Health | CVS Health | \$8,000.0 |
| Mar 2023 | Robins Landing | Pennant Group | N/A |
| Jan 2023 | Welvie | OMERS Private Equity | N/A |
| Jan 2023 | Corporate Health Solutions | Archetype Growth | N/A |
| Jan 2023 | Magellan Health | Evolent Health | \$800.0 |



| Company Name | Enterprise Value (\$M) |
|--------------------------|------------------------|
| UnitedHealth Group, Inc. | \$510,897.6 |
| Elevance Health, Inc. | \$132,692.4 |
| The Cigna Group | \$102,669.1 |
| Humana Inc. | \$72,495.6 |
| Centene Corporation | \$46,925.2 |
| Molina Healthcare, Inc. | \$15,683.6 |





Citations

Page 1:

1. Mergermarket. Accessed January 19, 2023. Data as of January 19, 2023.

Page 5:

- 1. Sector trends in Q1, 2023.
 - a. McKinsey & Company. The future of US healthcare: What's next for the industry post-COVID-19.
 https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/the-future-of-us-healthcare-whats-next-for-the-industry-post-covid-19. Accessed April 17, 2023.
- 2. Relevant transactions in Q4, 2022.
 - a. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.
- 3. Select public comparables set in Q4, 2022.
 - a. S&P Capital IQ. Accessed April 17, 2023. Data as of April 17, 2023.
- 4. Expanded public comparables set in Q4, 2022.
- a. S&P Capital IQ. Accessed April 17, 2023. Data as of April 17, 2023.

Page 6:

- 1. Sector trends in Q1, 2023.
 - a. <u>Forbes.</u> The Future of Healthcare Technology. https://www.forbes.com/sites/forbestechcouncil/2022/01/11/the-future-of-healthcare-technology/?sh=2e79087f4750. Accessed April 17, 2023.
- 2. Relevant transactions in Q1, 2023.
 - a. S&P Capital IQ. Accessed April 17, 2023. Data as of April 17, 2023.
- 3. Select public comparables set in Q1, 2023.
 - a. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.
- 4. Expanded public comparables set in Q1, 2023.
 - a. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.

Page 7:

- 1. Sector trends in Q1, 2023.
 - a. <u>Avenga. Future of Pharma & Life Sciences</u>
 https://www.avenga.com/magazine/pharmaceutical-industry-trends/. Accessed April 17, 2023.
- 2. Relevant transactions in Q1, 2023.
 - a. S&P Capital IQ. Accessed April 17, 2023. Data as of April 17, 2023.
- 3. Select public comparables set in Q1, 2023.
 - a. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.
- 4. Expanded public comparables set in Q1, 2023.
 - a. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.

Page 8:

- 1. Sector trends in Q1, 2023.
 - a. IQVIA. Trends Shaping the Medical Device Industry. https://www.iqviamedicalsalescareers.com/article/2022-8/what-are-the-trends-shaping-the-medical-devices-industry. Accessed April 17, 2023.
 - b. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.
- 2. Select public comparables set in Q1, 2023.
 - a. S&P Capital IQ. Accessed April 17, 2023. Data as of April 17, 2023.
- Expanded public comparables set in Q1, 2023.
 - a. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.

Page 9:

- 1. Sector trends in Q1, 2023.
 - a. <u>Healthcare Business Today.</u> Healthcare Payor Tends to Watch in 2023. https://www.healthcarebusinesstoday.com/healthcare-payor-trends-to-watch-in-2023/. Accessed April 17, 2023.
- 2. Relevant transactions in Q1, 2023.
 - a. <u>S&P Capital IQ</u>. Accessed April 17, 2023. Data as of April 17, 2023.
- 3. Select public comparables set in Q1, 2023.
 - a. S&P Capital IQ. Accessed April 17, 2023. Data as of April 17, 2023.
- 4. Expanded public comparables set in Q1, 2023.
 - a. S&P Capital IQ. Accessed April 17, 2023. Data as of April 17, 2023.



This newsletter is a periodic compilation of certain completed and announced merger and acquisition activity. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have "long" and "short" positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by

About Deloitte Corporate Finance

Deloitte Corporate Finance LLC (DCF), a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC), is an indirect wholly-owned subsidiary of Deloitte Financial Advisory Services LLP and affiliate of Deloitte Transactions and Business Analytics LLP. Investment banking or other services that would require registration as a broker-dealer with the SEC and membership in FINRA would be provided exclusively by DCF. For more information, visit www.investmentbanking.deloitte.com. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (DTTL), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as Deloitte Global) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Copyright © 2023 Deloitte Development LLC. All rights reserved.